Skip to content

Effect and mechanism of metformin on plasma secretagogin expression in patients with prediabetes

Effect and mechanism of metformin on plasma secretagogin expression in patients with prediabetes

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900023472
Enrollment
Unknown
Registered
2019-05-30
Start date
2019-06-01
Completion date
Unknown
Last updated
2019-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prediabetes

Interventions

Control:No
Pre-diabet dietary and exercise intervention group:Dietary and exercise
Pre-diabetes metformin intervention group:metformin

Sponsors

The First Affiliated Hospital of University of South China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Normal healthy person inclusion criteria: according to WHO 1999 diabetes diagnostic criteria, fasting plasma glucose in healthy normal people =7.0mmol/L, plasma glucose =7.8mmol/L 2h after sugar load; 24 kg/m2=BMI<28 kg/m2; 18 years old = age = 65 years old; signed informed consent book for pre-diabetes patients: According to the WHO 1999 standard, impaired fasting glucose and impaired glucose tolerance (6.1 mmol/L = fasting plasma glucose = 7.0 mmol/L, 7.8 mmol/L = 2 h after glucose load, plasma glucose = 11.1 mmol/L); 24 kg /m2=BMI<28 kg/m2; 18 years old = age =65 years old; no treatment with hypoglycemic drugs; patients have signed informed consent

Exclusion criteria

Exclusion criteria: Normal health person exclusion criteria: 1 Patients diagnosed with drug control for type 1 or type 2 diabetes. 2 Dyslipidemia (exceeding the guidelines for the prevention and treatment of type 2 diabetes in China (2017 edition)). 3 Liver and kidney dysfunction (total bilirubin > 21µmol / L, direct bilirubin > 6.8µmol / L, alanine aminotransferase > 80U / L, aspartate aminotransferase > 80U / L; urea > 7.5U / L, creatinine > 130µmol /L, uric acid > 420 µmol / L). 4 Combined with other organic chronic diseases (such as those who need medication for severe cardiovascular disease), endocrine dysfunction, abnormal mental illness, active gastrointestinal ulcers, infectious diseases (medication required), infectious diseases (tuberculosis, AIDS). 5 Oral or intravenous glucocorticoids in the past 3 months; weight loss drugs used more than 1 month; drug abusers. 6 Pregnant intentions during pregnancy, lactation or study period. 7 Any other circumstances that the investigator considers to be unsuitable for participation in the trial. Exclusion criteria for pre-diabetes patients: Refer to the exclusion criteria for healthy people, increase the inability to adhere to the full course of metformin treatment; poor self-control ability, can not adhere to diet exercise intervention; eating habits contrary to this trial.

Design outcomes

Primary

MeasureTime frame
Secretagogin;

Secondary

MeasureTime frame
Serum insulin;plasma C-peptide;Hemoglobin A1c;total bilirubin;alanine aminotransferase;aspartate aminotransferase;urea;creatinine;uric acid;Triglyceride;cholesterol;Low-density lipoprotein;High density lipoprotein;Plasma glucose;body weight;height;blood pressure;Urine routine;

Countries

China

Contacts

Public ContactJing Yang

The First Affiliated Hospital of University of South China

327753010@qq.com+86 18673411057

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026